| Table A | Cardiovascular Mortality in Pediatric CKD Stage 5 |
| Table B | Autopsy Studies of Cardiac Pathology in Pediatric CKD Stage 5 |
| Table C | Prevalence of Cardiovascular Risk Factors in Pediatic CKD Stage 5 |
| Table 1 | Comparison of Surgical Interventions for CAD To Prevent Future Cardiovascular Outcomes |
| Table 2 | Effect of Tissue versus Nontissue Valve Replacement on Prevention of Future Cardiovascular Outcomes |
| Table 3 | Presence of Systolic Dysfunction on Echocardiogram as a Predictor of Future CVD Outcomes |
| Table 4 | Increased LV Mass Index on Echocardiogram as a Predictor of Future Cardiovascular Outcomes |
| Table 5 | Dosage Adjustments and Drugs To Be Avoided |
| Table 6 | AHA Guidelines for the Prevention, Screening and Evaluation, and Treatment of Stroke, with KDOQI Modifications |
| Table 7 | Association of Low Ankle-Arm Brachial Index with Risk of Cardiovascular Outcomes |
| Table 8 | Oral Hypoglycemic Agents Contraindicated or to be used with Caution in Dialysis Patients |
| Table 9 | Antihypertensive Agents Contraindicated or to be used with Caution in Dialysis Patients |
| Table 10 | Removal of Antihypertensive Drugs with Dialysis |
| Table 11 | Factors Implicated in the Pathogenesis of Hypertension in Dialysis Patients |
| Table 12 | Antihypertensive Drug Therapy in Dialysis: Guidelines for Selection |
| Table 13 | Causes of Resistant Hypertension in Dialysis Patients |
| Table 14 | Association of Current Smoking with Risk of Cardiovascular Outcomes |
| Table 15 | Psychometric Testing Instruments |
| Table 16 | Association of Low Serum Calcium Level with Risk of Cardiovascular Outcomes and Markers |
| Table 17 | Association of Elevated Serum Calcium-Phosphorus Product with Risk of Cardiovascular Outcomes and Markers |
| Table 18 | Association of Elevated Serum Phosphorus Level with Risk of Cardiovascular Outcomes and Markers |
| Table 19 | Association of Serum PTH Level with Risk of Cardiovascular Outcomes and Markers |
| Table 20 | Factors Related to IDH Treatment |
| Table 21 | Association of Elevated Random Troponin I Levels with Risk of Cardiovascular Outcomes |
| Table 22 | Association of Elevated Random Troponin T Levels with Risk of Cardiovascular Outcomes |
| Table 23 | Association of Elevated Serum CRP Level with Risk of Cardiovascular Outcomes and Markers |
| Table 24 | Markers That Could Be Used To Assess Oxidative Stress in CKD |
| Table 25 | Potential Effects of ω-3 Fatty Acids on CVD Risk Factors |
| Table 26 | Summary of Effects of Fatty Acid Types on Lipid Classes |
| Table 27 | Amount of ω-3 Fatty Acids Provided by Selected Food Sources and Supplements |
| Table 28 | Alpha-Linolenic Acid (LNA) and Potassium (K+) Content of Selected Foods per 100 g |
| Table 29 | Association of the Lp(a) Concentration with Risk of CVD or Markers |
| Table 30 | Association of the apo(a) Polymorphism with Risk of CVD or Markers |
| Table 31 | Factors Contributing to Wasting in CKD Patients |
| Table 32 | Factors That May Affect Serum Albumin Levels in CKD Patients |
| Table 33 | Assessment of Wasting in CKD Patients |
| Table 34 | Association of SGA Score >1 with Risk of Cardiovascular Outcomes and Markers |
| Table 35 | Approximate Definition of Categories of Family History in the General Population |
| Table 36 | Association of the MTHFR 677C→T Polymorphism with Risk of Prevalent CVD or Markers |
| Table 37 | Association of the ApoE Polymorphism with Risk of CVD or Markers |
| Table 38 | Association of the ACE Polymorphism with Risk of CVD or Markers |
| Table 39 | Example of Format for Summary Tables |
| Table 40 | Format for Guidelines |
| Table 41 | Rating the Strength of Guideline Recommendations |
| Table 42 | Rating the Strength of the Evidence |